Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

AADI
Aadi Bioscience, Inc. Common Stock
stock NASDAQ

Inactive
Mar 18, 2025
2.05USD-2.381%(-0.05)79,185
Pre-market
0.00USD-100.000%(-2.10)0
After-hours
0.00USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
10:11AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 11, 2022   Benzinga
05:08AM EST  Jefferies Initiates Coverage On Aadi Bioscience with Buy Rating, Announces Price Target of $45   Benzinga
Jan 4, 2022
04:30PM EST  Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect   GlobeNewswire Inc
Nov 28, 2021
09:43AM EST  The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week   Benzinga
Nov 24, 2021
11:11AM EST  What 4 Analyst Ratings Have To Say About Aadi Bioscience   Benzinga
06:12AM EST  HC Wainwright & Co. Maintains Buy on Aadi Bioscience, Raises Price Target to $49   Benzinga
Nov 23, 2021
08:10AM EST  The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug   Benzinga
07:32AM EST  Aadi Bioscience, Inc. (AADI), a company focused on precision therapies, said on Tuesday that the U.S. Food and Drug Administration or FDA has approved FYARRO, sirolimus protein-bound particles for injectable suspension or albumin-bound to treat locally advanced metastatic malignant perivascular epithelioid cell tumor, known as PEComa.   RTTNews
06:17AM EST  Aadi Bioscience: FDA Approves FYARRO For Patients With Malignant PEComa   RTTNews
06:08AM EST  Aadi Bioscience Announces FDA Approval Of FYARRO   Benzinga
06:00AM EST  -- FYARRO is the first and only approved therapy for adults for the treatment of malignant PEComa, an ultra-rare and aggressive form of sarcoma with a strong female predominance -- FYARRO launch planned for Q1 2022; Investor call to be held today at 8:30 am ET   GlobeNewswire Inc
Nov 21, 2021
03:05PM EST  The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week   Benzinga
Nov 15, 2021
08:00AM EST  UPDATE Aadi Bioscience Presents Two Abstracts   GlobeNewswire Inc
Nov 13, 2021
01:35PM EST  Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus)   GlobeNewswire Inc
Nov 10, 2021
07:56AM EST  Aadi Bioscience Q3 EPS $(9.17) Down From $(1.23) YoY   Benzinga
07:00AM EST  Aadi Reports Third Quarter 2021 Financial Resultsand   GlobeNewswire Inc
Nov 9, 2021
08:00AM EST  Aadi Bioscience, Inc. (Aadi), clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that management will be participating in the upcoming Jefferies London Healthcare Conference and the Piper Sandler Virtual Healthcare Conference.   GlobeNewswire Inc
Nov 2, 2021
10:54AM EDT  The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US   Benzinga
10:23AM EDT  Aadi Bioscience Appoints Scott Giacobello As Chief Financial Officer   Benzinga
Oct 25, 2021
08:00AM EDT  Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer   GlobeNewswire Inc
Oct 22, 2021
08:09AM EDT  Aadi Bioscience Highlights Publication Of Phase 2 Registrational (AMPECT) Trial Of nab-Sirolimus In Patients With Malignant Perivascular Epithelioid Cell Tumors In Journal Of Clinical Oncology   Benzinga
08:00AM EDT  Aadi Bioscience Announces Publication of its Phase 2   GlobeNewswire Inc
Oct 19, 2021
05:22PM EDT  Aadi Bioscience, Inc. (Aadi), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., willpresent at H.C. Wainwrights 2nd Annual Precision Oncology Conference, which will be held virtually.   GlobeNewswire Inc
Oct 6, 2021
08:06AM EDT  Aadi Bioscience To Present New Preclinical Data On Nab-Sirolimus At AACR-NCI-EORTC Virtual International Conference   Benzinga
08:00AM EDT  - Poster Presentation to go Live on October 7, 2021 at 9 a.m. ET and on Demand at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics -   GlobeNewswire Inc
Oct 1, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 1, 2021   Benzinga
07:10AM EDT  Cowen & Co. Initiates Coverage On Aadi Bioscience with Outperform Rating   Benzinga
Sep 20, 2021
08:38AM EDT  Aadi Bioscience Appoints Brendan Delaney As Chief Operating Officer   Benzinga
08:35AM EDT  Aadi Bioscience Appoints Brendan Delaney As COO   RTTNews
08:30AM EDT  Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer   GlobeNewswire Inc
Sep 14, 2021
10:16AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2021   Benzinga
08:09AM EDT  Ladenburg Thalmann Initiates Coverage On Aadi Bioscience with Buy Rating, Announces Price Target of $51   Benzinga
Sep 13, 2021
08:00AM EDT  Aadi Bioscience Appoints Emma Reeve to its Board of Directors   GlobeNewswire Inc
Sep 8, 2021
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2021   Benzinga
06:17AM EDT  Piper Sandler Initiates Coverage On Aadi Bioscience with Overweight Rating, Announces Price Target of $45   Benzinga
Aug 30, 2021
06:19AM EDT  HC Wainwright & Co. Maintains Buy on Aadi Biosciences, Inc. - Common Stock, Raises Price Target to $47   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC